Laser Clinique is proud to announce that the FDA has approved Xeomin®.

First there was Botox® Cosmetic, then there was Dysport®, and now there is Xeomin® (incobotulinumtoxinA). This new botulinum toxin type A is used  to treat severe frown lines or "11's" between the eyebrows.  It is also used to treat forehead lines and crow's feet.

Xeomin® was already FDA approved for use in adults with cervical dystonia and blepharospasm.  Abnormal neck pain and movements characterize cervical dystonia, and abnormal, involuntary blinking or spasm of the eyelids marks blepharospasm.  Xeomin® is manufactured by Merz Pharmaceuticals, and has been used by more than 84,000 people worldwide. It is now approved for use in 20 countries.  Xeomin® has been used extensively across Europe to diminish wrinkles and give patients a younger, refreshed look. Its FDA approval in the United States will open a new door for the company and give those interested in cosmetic treatments an additional option when it comes to wrinkle removal and anti-aging procedures.

Xeomin® is a “naked injectable,” meaning that it does not contain any additives.  Xeomin’s results can last three to four months. The major benefit of a pure-form injectable is that the human body is less likely to become resistant to Xeomin® because there are simply less ingredients in the solution.  Some patients have developed antibodies to Botox® Cosmetic and Dysport®, leading their bodies to reject the treatments or rendering them less effective.

Side effects are also similar due to the same active ingredient: minor swelling, bruising, headache, and soreness are considered normal immediately after treatment and should fade within a few days.